H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 24.06 HKD -0.17% Market Closed
Market Cap: HK$21B

Net Margin

9.9%
Current
Improving
by 9.9%
vs 3-y average of 0%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.9%
=
Net Income
$466.9m
/
Revenue
$602.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.9%
=
Net Income
HK$466.9m
/
Revenue
$602.2m

Peer Comparison

Country Company Market Cap Net
Margin
HK
HUTCHMED (China) Ltd
HKEX:13
21.1B HKD
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Higher than 80% of companies in Hong Kong
Percentile
80th
Based on 3 006 companies
80th percentile
9.9%
Low
-239 513 300% — -12.9%
Typical Range
-12.9% — 5.3%
High
5.3% — 203 056%
Distribution Statistics
Hong Kong
Min -239 513 300%
30th Percentile -12.9%
Median 0.5%
70th Percentile 5.3%
Max 203 056%

HUTCHMED (China) Ltd
Glance View

Market Cap
21B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.

HUTCHMED (China) Ltd Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
9.9%
=
Net Income
$466.9m
/
Revenue
$602.2m
What is HUTCHMED (China) Ltd's current Net Margin?

The current Net Margin for HUTCHMED (China) Ltd is 9.9%, which is above its 3-year median of 0%.

How has Net Margin changed over time?

Over the last 3 years, HUTCHMED (China) Ltd’s Net Margin has increased from -8.1% to 9.9%. During this period, it reached a low of -10.8% on Dec 31, 2022 and a high of 9.9% on Jun 30, 2025.

Back to Top